Literature DB >> 23772039

Inflammatory cytokine-mediated evasion of virus-induced tumors from NK cell control.

Rabinarayan Mishra1, Bojan Polic, Raymond M Welsh, Eva Szomolanyi-Tsuda.   

Abstract

Infections with DNA tumor viruses, including members of the polyomavirus family, often result in tumor formation in immune-deficient hosts. The complex control involved in antiviral and antitumor immune responses during these infections can be studied in murine polyomavirus (PyV)-infected mice as a model. We found that NK cells efficiently kill cells derived from PyV-induced salivary gland tumors in vitro in an NKG2D (effector cell)-RAE-1 (target cell)-dependent manner; but in T cell-deficient mice, NK cells only delay but do not prevent the development of PyV-induced tumors. In this article, we show that the PyV-induced tumors have infiltrating functional NK cells. The freshly removed tumors, however, lack surface RAE-1 expression, and the tumor tissues produce soluble factors that downregulate RAE-1. These factors include the proinflammatory cytokines IL-1α, IL-1β, IL-33, and TNF. Each of these cytokines downregulates RAE-1 expression and susceptibility to NK cell-mediated cytotoxicity. CD11b(+)F4/80(+) macrophages infiltrating the PyV-induced tumors produce high amounts of IL-1β and TNF. Thus, our data suggest a new mechanism whereby inflammatory cytokines generated in the tumor environment lead to evasion of NK cell-mediated control of virus-induced tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23772039      PMCID: PMC3711091          DOI: 10.4049/jimmunol.1203328

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.

Authors:  Jack D Bui; Leonidas N Carayannopoulos; Lewis L Lanier; Wayne M Yokoyama; Robert D Schreiber
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

2.  TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.

Authors:  Günter Eisele; Jörg Wischhusen; Michel Mittelbronn; Richard Meyermann; Inja Waldhauer; Alexander Steinle; Michael Weller; Manuel A Friese
Journal:  Brain       Date:  2006-08-03       Impact factor: 13.501

3.  Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.

Authors:  Santanu Dasgupta; Malaya Bhattacharya-Chatterjee; Bert W O'Malley; Sunil K Chatterjee
Journal:  J Immunol       Date:  2005-10-15       Impact factor: 5.422

4.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Authors:  S Bauer; V Groh; J Wu; A Steinle; J H Phillips; L L Lanier; T Spies
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

5.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

6.  Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein.

Authors:  Milena Hasan; Astrid Krmpotic; Zsolt Ruzsics; Ivan Bubic; Tihana Lenac; Anne Halenius; Andrea Loewendorf; Martin Messerle; Hartmut Hengel; Stipan Jonjic; Ulrich H Koszinowski
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Radiation-resistant and radiation-sensitive forms of host resistance to polyomavirus.

Authors:  J P Carroll; J S Fung; R T Bronson; E Razvi; T L Benjamin
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Proteolytic release of soluble UL16-binding protein 2 from tumor cells.

Authors:  Inja Waldhauer; Alexander Steinle
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

9.  Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.

Authors:  Lizzia Raffaghello; Ignazia Prigione; Irma Airoldi; Marta Camoriano; Isabella Levreri; Claudio Gambini; Daniela Pende; Alexander Steinle; Soldano Ferrone; Vito Pistoia
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

10.  NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145.

Authors:  Astrid Krmpotic; Milena Hasan; Andrea Loewendorf; Tanja Saulig; Anne Halenius; Tihana Lenac; Bojan Polic; Ivan Bubic; Anja Kriegeskorte; Ester Pernjak-Pugel; Martin Messerle; Hartmut Hengel; Dirk H Busch; Ulrich H Koszinowski; Stipan Jonjic
Journal:  J Exp Med       Date:  2005-01-10       Impact factor: 14.307

View more
  4 in total

1.  Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Authors:  Ji Young Yoo; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Hongsheng Dai; Tejaswini Nallanagulagari; Jeffrey Wojton; Brian S Hurwitz; Theresa Relation; Tae Jin Lee; Michael T Lotze; Jun-Ge Yu; Jianying Zhang; Carlo M Croce; Jianhua Yu; Michael A Caligiuri; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2016-07-07       Impact factor: 12.531

Review 2.  NK cells and virus-related cancers.

Authors:  Rabinarayan Mishra; Raymond Welsh; Eva Szomolanyi-Tsuda
Journal:  Crit Rev Oncog       Date:  2014

Review 3.  The Role of IL-33/ST2 Pathway in Tumorigenesis.

Authors:  Kristen M Larsen; Maydelis Karla Minaya; Vivek Vaish; Maria Marjorette O Peña
Journal:  Int J Mol Sci       Date:  2018-09-09       Impact factor: 5.923

4.  The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma.

Authors:  Satoshi Nagaoka; Daisaku Yamada; Hidetoshi Eguchi; Yuki Yokota; Yoshifumi Iwagami; Tadafumi Asaoka; Takehiro Noda; Koichi Kawamoto; Kunihito Gotoh; Shogo Kobayashi; Eiji Miyoshi; Yuichiro Doki; Masaki Mori
Journal:  Cancer Sci       Date:  2020-11-24       Impact factor: 6.518

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.